BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10066660)

  • 1. Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.
    Gan J; Kendra K; Ricci M; Hank JA; Gillies SD; Sondel PM
    Clin Diagn Lab Immunol; 1999 Mar; 6(2):236-42. PubMed ID: 10066660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
    Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost JD; Rakhmilevich A; Hank JA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 1999 Aug; 48(5):219-29. PubMed ID: 10478638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
    Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
    Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
    Chen TT; Tao MH; Levy R
    J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.
    Wadhwa M; Meager A; Dilger P; Bird C; Dolman C; Das RG; Thorpe R
    Immunology; 2000 Jan; 99(1):113-23. PubMed ID: 10651949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
    Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA.
    Soman G; Yang X; Jiang H; Giardina S; Mitra G
    J Immunol Methods; 2011 Oct; 373(1-2):181-91. PubMed ID: 21893062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine].
    Liu H; Zhu P; Lin NJ; Zhang Y; Bu DF; Wang YJ; Wang YQ; Yang Y
    Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):48-53. PubMed ID: 14990159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins.
    Gillies SD; Young D; Lo KM; Roberts S
    Bioconjug Chem; 1993; 4(3):230-5. PubMed ID: 8324014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An enzyme linked immunosorbent assay for the detection of human interleukin 3 in serum.
    Pauly JU; Heder A; Kurrle R; Seiler FR
    Behring Inst Mitt; 1991 Dec; (90):104-11. PubMed ID: 1801686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cocktail of three monoclonal antibodies significantly increases the sensitivity of an enzyme immunoassay for human granulocyte-macrophage colony-stimulating factor.
    Zenke G; Strittmatter U; Tees R; Andersen E; Fagg B; Kocher HP; Schreier MH
    J Immunoassay; 1991; 12(2):185-206. PubMed ID: 1710626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
    Hornick JL; Khawli LA; Hu P; Lynch M; Anderson PM; Epstein AL
    Blood; 1997 Jun; 89(12):4437-47. PubMed ID: 9192768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.